Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Psyched Wellness (PSYC) has received Health Canada approval to have the Amanita Muscaria mushroom added to the Natural Health Products Ingredients Database (NHPID)
  • This approval moves the company closer to bringing its Amanita-based CPG products to market o promote stress relief, relaxation and assist with restful sleeping
  • Jeff Stevens, CEO of Psyched Wellness sat down with Caroline Egan to elaborate on this achievement
  • Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods
  • Psyched Wellness Ltd (PSYC) is up 2.94 per cent, trading at C$0.175 per share at 1:45 pm ET

Psyched Wellness (PSYC) announced that the Amanita Muscaria mushroom has been added to the Natural Health Products Ingredients Database (NHPID) of Canada.

Jeff Stevens, CEO of Psyched Wellness sat down with Caroline Egan to elaborate on this achievement.

“The addition of Amanita Muscaria to the NHPID is a significant achievement and is the result of extensive research that Psyched has undertaken to demonstrate its natural medicinal properties. This milestone moves us closer to being able to bring our Amanita-based CPG products to market which we are developing to promote stress relief, relaxation and assist with restful sleeping through the natural calming powers of AME-1.”

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.

Psyched Wellness Ltd (PSYC) is up 2.94 per cent, trading at C$0.175 per share at 1:45 pm ET.

More From The Market Herald
The Market Herald Video

" LUXXFOLIO Holdings (CSE:LUXX) provides operational update

LUXXFOLIO Holdings’ (LUXX) November updates includes record mining revenues of approximately $1.8 million and monthly rewards of 23.5 Bitcoin.
The Market Herald Video

" FSD Pharma (CSE:HUGE) demonstrates positive effects of Lucid-MS in treating MS in pre-clinical models

FSD Pharma (HUGE) is sharing pre-clinical data demonstrating the potentially disease-modifying effects of its lead drug candidate Lucid-MS.
The Market Herald Video

" Baselode Energy (TSXV:FIND) closes $9.2M private placement

Baselode Energy (FIND) has closed its “bought deal” private placement for aggregate proceeds of $9,200,632.50, including the exercise of the over-allotment option.